The United Kingdom and the United States have hammered out a major trade agreement that will keep zero tariffs on UK pharmaceutical products entering the US market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to increase spending on medicines through the National Health Service (NHS). This pledge ensures that duties on these vital goods will stay at nothing for a timeframe of the next three years.
This deal is in response to earlier threats to dramatically increase tariffs on patented drug products, with potential rates floated up to one hundred percent.
"This arrangement between the UK reinforces the worldwide climate for cutting-edge drugs and establishes long-overdue balance to transatlantic drug exports," an announcement said.
Economic Significance
Drugs constitute one of the the United Kingdom's biggest export categories to the US, which is clearly the largest buyer for large British pharmaceutical firms.
Trade data indicate that in the 12 months to the end of the third quarter, the UK exported medicines valued at £11.1bn to the US. This value accounted for 17.4% of British export trade in that span.
"This guarantee protects work, increases capital expenditure and sets the stage for the UK to become a international leader for life sciences," the Business and Trade Secretary commented.
Key NHS Changes
The pact includes several key commitments from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new therapies to be too expensive by 25%.
- Boosted Medicine Funding: There is a goal to double overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to stay within budget will be limited at fifteen percent. In the past, rebates were more than 20%.
Industry Background
The deal takes place against a long-running row between the pharmaceutical industry and the UK government over medicine costs and approval rates.
This friction were intensified by assertions that US patients were charged several times more for the identical medicines than patients in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been paused or scrapped, while substantial investments have been announced toward US facilities.
A senior figure stated that the NHS needed to increase expenditure on drugs, noting that its expenditure on drugs had declined as a percentage of its resources over the last ten years.
